1. Home
  2. CNOB vs ABCL Comparison

CNOB vs ABCL Comparison

Compare CNOB & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ConnectOne Bancorp Inc.

CNOB

ConnectOne Bancorp Inc.

N/A

Current Price

$32.19

Market Cap

1.6B

Sector

Finance

ML Signal

N/A

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$10.59

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNOB
ABCL
Founded
1982
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
3.5B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
CNOB
ABCL
Price
$32.19
$10.59
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$31.25
$8.40
AVG Volume (30 Days)
379.7K
9.0M
Earning Date
04-23-2026
05-11-2026
Dividend Yield
2.48%
N/A
EPS Growth
N/A
10.91
EPS
1.51
N/A
Revenue
N/A
$75,128,000.00
Revenue This Year
$42.85
N/A
Revenue Next Year
$7.27
$21.85
P/E Ratio
$21.37
N/A
Revenue Growth
N/A
160.56
52 Week Low
$23.20
$2.75
52 Week High
$34.14
$12.15

Technical Indicators

Market Signals
Indicator
CNOB
ABCL
Relative Strength Index (RSI) 44.09 66.21
Support Level $31.36 $3.38
Resistance Level $33.95 N/A
Average True Range (ATR) 0.52 0.90
MACD -0.13 0.23
Stochastic Oscillator 23.18 77.49

Price Performance

Historical Comparison
CNOB
ABCL

About CNOB ConnectOne Bancorp Inc.

ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets, and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental, and consumer wages.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: